Open Access Research Article
TRIPS WAIVER : THE HUMANITARIAN SAVIOUR DURING COVID-19 PANDEMIC
Published Paper
Article Details
TRIPS WAIVER : THE HUMANITARIAN
SAVIOUR DURING COVID-19 PANDEMIC
AUTHORED BY
- RUCHITA SRIVASTAVA
& KUMARI PRAGATI
ABSTRACT
The World Trade Organization was
established in 1995, and countries have been bound by the Trade Related Aspects
of Intellectual Property Rights since then (TRIPS). The agreement includes a
comprehensive plan for patenting and protecting medical supply units, including
vaccines and diagnostics. Recently, developing countries such as India and
South Africa have demanded TRIPS waivers for all developing countries to gain
access to vaccines. The requested TRIPS waiver would apply to COVID19 vaccines,
diagnosis, and treatment. The waiver is significant because it would allow
member states to conduct vaccine research, manufacturing, and distribution. The
developing countries' proposal for a temporary waiver of IP rights claims that
IP could stymie the supply of COVID19 drugs and vaccines. However, there is no
near consensus because most developed countries oppose this stance and even
argue that waiving TRIPS will not increase manufacturing. The pharmaceutical
industry is also opposed to developing countries' stance, arguing that waiving
intellectual property rights will stifle future research and development. The
article investigates whether the TRIPS Council's discussions, debates, and
negotiations on the proposed waiver are likely to result in a useful solution.
We provide a brief commentary that highlights the flaws and specifies the
minimum changes required for a meaningful workable text for use in the COVID-19
emergency context.
KEY WORDS: Developmental Countries, Public Health, TRIPS, Vaccines,
Waiver
BACKGROUND
Patents grant the sole ownership of
an intangible creation of the human mind.
The rules for patents state that they must be available for any
invention or process. The patent holder exempted others from making, using, or
selling his/her invention for a period of 20 years. The successful completion
of the Uruguay round in 1994 was the first step in the introduction of patents[1].
The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
is the first multilateral treaty to establish the fundamental criteria for
patentable subject matter.
Developed-country governments, such as the United States, were strongly
promoting global intellectual property (IP) harmonization, despite strong
opposition from developing-country governments[2].There
was a demand for mandatory extension of patent protection for pharmaceutical
products, which would have serious consequences for domestic pharmaceutical
industries. Nonetheless, the demand for stronger and more internationally
harmonized intellectual property rights (IPRs) resulted in the creation of
TRIPS, which is widely regarded as the most ambitious IPRs agreement in history[3]. Article 7 of the TRIPS agreement states the
goal of IPR protection in terms of rights and obligations. Article 8 states that WTO member countries
may take measures necessary to protect public health as long as they are
consistent with the TRIPS agreement. The
implementation of these measures necessitates a balance between the country's
international and national needs[4].
The Doha Declaration (adopted at the WTO ministerial conference in 2001)
outlines the goals outlined in Article 7 of the agreement. It aligns the goals
of intellectual property protection with public health policy. There is no
universal way to view patents; they differ from country to country[5].
The requirement to implement patent
protection in 2005, with subsequent protection for 20 years, altered the market
based conditions for pharmaceuticals in international trade. According to Article IX.3 of the Marrakesh
Agreement, only in exceptional circumstances can a ministerial conference waive
the conditions imposed on WTO member countries.
The TRIPS IPRs system provides companies with protection, including a
time-limited monopoly on marketing their products. TRIPS provides parties with autonomy, as
stated in Article 1 of the agreement, which states that members are free to
determine their own appropriate method for implementing the provision within
their own domain of legal system. The
TRIPS agreement's goal is to liberalize international trade while protecting
intellectual property rights. According
to Article 8, it seeks to strike a balance between private and public rights in
protecting public health and nutrition, as well as economic and technological
development. To summarize, IP allows for the creation and distribution of
innovation, and their product piques the interest of increasing the number of
commercially and serving public interest[6].
INTRODUCTION
The COVID-19 pandemic has once again
focused attention on the World Trade Organization (WTO) and other international
organizations. In particular, when it comes to intellectual property rights,
the World Trade Organization's Council for Trade-Related Aspects of
Intellectual Property Rights (TRIPS Council) is once again at the Centre of
discussions and debates about what the precise and appropriate role of intellectual
property rights should be in a public health crisis such as a pandemic[7].
There is a sense of déjà vu in this regard because, in the early 2000s, just
around 6 years after the WTO's Agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS Agreement) entered into force; the TRIPS
Council was required to respond to the demands of developing and
least-developed countries for intellectual property protection[8].
The COVID-19 pandemic has drawn
attention to the World Trade Organization (WTO) and other international
organizations’ once more. In particular, the World Trade Organization's Council
for Trade-Related Aspects of Intellectual Property Rights (TRIPS Council) is
once again at the center of discussions and debates about what the precise and
appropriate role of intellectual property rights should be in a public health
crisis such as pandemic.[9] In
this regard, there is a sense of déjà vu because, in the early 2000s, just
around 6 years after the WTO's Agreement on Trade-Related Aspects of Intellectual
Property Rights (TRIPS Agreement) entered into force; the TRIPS Council was
required to respond to the demands of developing and least-developed countries
for intellectual property.
RELATIONSHIP BETWEEN TRIPS AND PUBLIC HEALTH ACCESS
The Doha Declaration acknowledges the
"gravity of the public health problems afflicting many developing and
least developed countries, particularly those caused by HIV/AIDS, Malaria,
Tuberculosis, and other epidemics." The declaration stated that this agreement
should be used to address both national and international problems that arise
as a result of public health issues. It is clear from the declaration that
public health is supreme and should not prevent members from taking steps to
protect public health rights. The agreement should be interpreted in such a way
that it gives the public health more clout.
Article 31 paragraph 5(b) of the Doha
Declaration states that "every WTO member has the right to grant
compulsory licenses and the freedom upon which such licenses’ are
granted." Compulsory licensing is defined as licenses issued by the
government to an applicant as authorization to make, use, or sell a patented
product.[10]This
serves as an exception to the general principle of TRIPS, and the waiver can be
granted to the respective countries as a result. Articles 30[11]
and 31[12]
of the TRIPS agreement require and allow WTO members to use patent subject
matter when the public interest is involved.
In the absence of voluntary licensing, compulsory licensing will
significantly reduce the cost of generic medicine and lead to improved patient
outcomes. The agreement only specifies the circumstances under which compulsory
licensing is granted, such as in an extreme emergency or for public
noncommercial use. Another condition mentioned is where the "domestic
market" will be supplied.[13]
The origins of paragraph 6 of the
Doha Declaration can be traced back to a proposal submitted by developing
countries requesting an interpretation of Article 30 of the TRIPS agreement to
allow member countries that lack resources to export and manufacture patented
medicines to third parties. This could ensure that not only COVID19 vaccines,
but also all products such as diagnostic kits, are affordable and accessible.[14]
Section 6 provides for two types of temporary waivers:
CRITICAL APPRAISAL OF COVID-19 WAIVER CASE
Proposed in October 2020, the waiver
was time-restricted and reason explicit, with its application barely customized
to the 'avoidance, regulation or treatment of Coronavirus ‘Albeit the first
text didn't set out the various items and advancements covered, Presentation 6
highlighted the need to advance the 'unhampered and opportune admittance to
reasonable clinical items including analytic units, immunizations, medications,
individual defensive gear and ventilators for a quick and successful reaction
to the Coronavirus pandemic'[15].
At the hour of the proposition, emerging nations were not just worried about
absence of reasonable admittance to required antibodies, diagnostics and
therapeutics, yet they additionally expected that they would experience issues
contending with created nations to procure these items and advancements. Their
apprehensions were not unwarranted, taking into account their previous negative
encounters with immunization openness during the H5N1 avian flu episode and the
H1N1 pandemic as well also recorded concerns about antibody patriotism during
the Coronavirus pandemic. [16]
Compounding an already painful situation, reports arisen soon after
accommodation of the first waiver suggestion that agricultural nations had been
charged greater costs than created nations for Coronavirus immunizations, due
maybe to the previous' powerlessness to buy huge quantities.[17]
Taken together, these imbalances without any problem clarify why agricultural
nations effectively requested critical changes for the Excursions based
licensed innovation framework to battle the worldwide pandemic[18].
To facilitate adoption of the
proposed COVID-19 TRIPS waiver, supporters advanced a number of arguments. The
first requires a patent holder to be compensated for compulsory licensing in
the importing country. The development of COVID-19 vaccines, for example,
involves not only patents in relevant vaccines, but also a wide range of
intellectual property rights in the underlying platform technologies - whether
mRNA, adenovirus, or more conventional ones.[19]The
difficulties in clearing these rights have resulted in what Michael Heller and
Rebecca Eisenberg have referred to as the 'tragedy of the anticommunist,'[20]
in which ‘multiple owners each have a right to exclude others Second, the
problem of patent thickets is not new in the field of public health. During the
SARS epidemic, researchers at Erasmus University in the Netherlands expressed a
similar concern: [Without the establishment of the proposed SARS Patent Pool,
it is likely that patent rights incorporating the SARS genomic sequence will be
fragmented across several groups. Sorting out these rights will be difficult,
and the law court may be called in.... [For firms considering developing a SARS
vaccine], uncertainty over patent rights makes this decision even more
difficult, because neither the future cost of licensing the patent rights nor
the availability of all necessary patents can be determined. As a result, the
incentive for vaccine manufacturers is to delay the decision to invest.
Third, the compulsory nature and
significant expenses of WTO question settlement[21]
have made numerous legislatures and their authority’s consistence oriented.[22]Expecting
that their nations will be hauled into the WTO debate settlement process and in
this way experience financial and reputational hurts, they have effectively
stayed away from endeavors that would reach or stretch the boundaries of
Outings adaptabilities, regardless of whether those endeavors could assist with
safeguarding general wellbeing. Generally, the waiver, whenever embraced, would
empower policymakers to boost their strategy space at the crossing point of
protected innovation and general wellbeing.
Fourth, and relatedly, worries about
rebelliousness with protected innovation norms are not restricted to the
Outings Arrangement. Legislatures and their authorities are similarly worried
about deviations from the high Outings in addition to norms tracked down in
created nations - the US, specifically. All things considered, the US Exchange
Act enables the US Exchange Delegate to make Area 301 moves against nations
that have neglected to give 'sufficient and viable security of protected
innovation freedoms despite the way that [they] might be in consistence with
the particular commitments of the [TRIPS] Understanding'.[23]
In the beyond twenty years, the US Exchange Delegate has made a move against
South Africa, Thailand and different nations giving WTO reasonable mandatory
licenses’.[24] By
pre-empting such activity, the waiver would serve a comparative capability as
Leader Request 13 155, which the Clinton Organization gave in May 2000. Taken
on after the worldwide drug industry's rash claim against President Nelson
Mandela's administration in South Africa, that request empowered nations in
sub-Saharan Africa to improve admittance to HIV/Helps prescriptions and related
clinical advances without the apprehension about exchange retaliation.[25]
Fifth, reception of the waiver could
actuate drug organizations and other confidential undertakings to turn out to
be all the more supportive of dynamic in giving willful licenses, including
those that sound open or vigorously limited, really. In the beginning of the
Coronavirus pandemic, pundits and the broad communications noticed Babies’ vow
to swear off authorization of its licenses in Altera, Moderna's guarantee to do
likewise for Coronavirus antibodies, Gilead's issuance of nonexclusive willful
licenses to remdesivir, and AstraZeneca's dynamic commitment with Brazil, India
and other emerging nations to increment worldwide admittance to vaccines.[26]Certainly,
these deliberate exercises occurred without the waiver. By and by, they
included choices made when right holders were worried of inevitable government
intervention.[27] It is
consequently not fantastical to expect that these right holders would have
acted correspondingly had the waiver been adopted.[28]
As Jayashree Watal, a previous WTO official and Outings mediator for India,
noticed, the waiver would act as a 'roundabout endeavor to come down on the
first producers to cooperate'.[29]
At long last, taking into account the size of the Coronavirus pandemic and its
gigantic difficulties to nations from around the world, changes in accordance
with the Excursions Arrangement are both sensible and justifiable. Similarly as
a country's constitution ought not be 'a self-destruction settlement' - a
paramount perception made by Equity Arthur Goldberg in Kennedy v.
Mendoza-Martinez[30] - the
Excursions Understanding shouldn't keep WTO individuals from tending to those
general wellbeing exigencies that undermine their prosperity, like Coronavirus.
In addition, given the Trans line nature of worldwide pandemics and the rise of
the delta, lambda, omicron and different variations in various regions of the
planet, the advantages of carrying out the waiver would acclimate to the whole
worldwide local area. A common mantra during the Coronavirus pandemic is
'[n]o-one is protected until everybody is protected'. It is hence nothing
unexpected that the South Place and different pundits have supported
utilization of the public safety special case under Article 73 of the
Excursions Consent to battle the pandemic.[31]
Whenever embraced, the waiver would have based on this suggestion while
pre-empting any likely test before the WTO Debate Settlement Body to the
arrangement's prerequisites concerning 'fundamental security interests', need
and the presence of a 'crisis in worldwide relations'.
Given these past arranged results, it
is easy to comprehend the reason why defenders of the Coronavirus Excursions
waiver needed to propel a lot more extensive proposition notwithstanding
expected resistance from some created country individuals. It is additionally
not outlandish to expect that these defenders and their cosponsors were very
much aware that they wouldn't have the option to get everything they proposed.
Figuring out what these nations ought to request toward the start of talks is
altogether different from figuring out what they ought to acknowledge toward
the end. In a posthumous examination Of the waiver, we shouldn't confound the
two. Finally, there are numerous decisions in dealings, and these decisions are
seldom double. Consider, for instance, the somewhat disputable issue of
suspending security of proprietary advantages and other undisclosed data.
Albeit the waiver's rivals over and over noticed their profound worries about
constrained exposure of proprietary innovations and undisclosed regulatory
data,[32]
there is a hole between suspension of proprietary advantage security and
constrained technology transfer,[33]
the two of which might be seen as a component of a continuum. The last option
remains profoundly disputable at the WTO and has drawn in Excursions In the
middle of between these two paired decisions are choices in an ill-defined
situation, for example, restricted revelation of administrative information and
other undisclosed data that had previously been submitted to government
organizations to get showcasing endorsement. [34]
The European Medications Office had previously worked with such divulgence
before the Coronavirus pandemic.[35] Further
inside the restricted divulgence choice are a few better grained decisions
about the extent of inclusion and the circumstances joined.
In total, the first waiver
proposition progressed by India and South Africa and the overhauled proposition
cosponsored by in excess of [36]
agricultural nations didn't keep nations from addressing the two sub-inquiries
in the positive. In any case, some strong created nations appeared to have
decided that they could never answer the second subquestion in the confirmed -
because of standards or reasoning, the need to keep up with near advantage,
homegrown industry resistance or different reasons. A significant number of
these nations were likewise uncertain if they could respond to the main
sub-question in the positive, despite the fact that they didn't object to the
sendoff of message based talks. In this manner, even after the send of these dealings at the Excursions Chamber,
they kept on scrutinizing the requirement for the waiver, alongside its
practicality what's more, adequacy[37].
Their persistent reluctance to draw in with the printed language in the
proposed waiver to a great extent makes sense of why the WTO enrollment at last
deserted the proposition and embraced the Ecclesiastical Choice instead. The
Coronavirus pandemic has unleashed destruction all through the world, costing a
huge number of human lives and demanding a worldwide monetary cost of several
trillions of dollars. Given the size of destruction, it is reasonable why India
and South Africa proposed a waiver that would suspend in excess of thirty
arrangements in the Excursions Consent to work with the 'counteraction,
regulation or treatment of Coronavirus[38]'.
It is likewise not unexpected for see in excess of 33% of the WTO participation
anxiously co-supporting the proposition. Without a doubt, as this section has
shown, it is hard to present areas of strength for an against the sendoff of
message put together exchanges with respect to the proposed waiver at the WTO.
Nevertheless, critical examination of the waiver proposition uncovers many
difficulties defying both discussion and execution. These moves in the long run
prompted the breakdown of dealings on the waiver and reception of an extremely
restricted clerical choice at MC12. By looking at the critical contentions for
and against the waiver proposition, this part shows the numerous intricacies
engaged with global approach banters at the convergence of protected innovation
and general wellbeing[39].
It shows that policymakers and reporters may unequivocally differ on beneficial
protected innovation strategies in any event, when they share a typical goal.
Generally, the waiver banter has foreshadowed many difficulties facing
worldwide arrangement banters on issues connecting with supportability,
advancement and worldwide equity.[40]
ANALYSIS
In October
2020, amid concerns over access to vaccines and treatment for COVID-19, India,
and South Africa proposed a temporary waiver of Sections 1, 4, 5, and 7 of Part
II of the Agreement on Trade-Related Aspects of Intellectual Property Rights
(TRIPS) in the WTO Council, which would allow increased production and
equitable distribution of such vaccines.[41]
It is not
the first time that the provisions of TRIPS have been proposed to waive off.
This waiver proposal is similar to the proposal made by Zimbabwe, at the WTO
TRIPS Council in 2001 at the height of the HIV/AIDS crisis, that the WTO could
no longer ignore access to medicine as “an issue that was being actively
debated outside the WTO, not within it”.[42] The
proposal to abolish intellectual property rights for patented HIV/AIDS
medicines was initially rejected by most developed countries, which argued that
such a measure would threaten the comprehensive system of patent protection
necessary to support research and innovation and that the flexibility of TRIPS
contained in Article 31 may only be invoked in the case of "a national
emergency and other situations of extreme urgency" as defined in Article
31(b).[43]
On the other hand, developing countries argued that Article 31 should be
interpreted leniently so that they could benefit most from compulsory licenses
and parallel imports.[44]
The developed and developing members thus presented two diametrically opposed
views on the clarification of TRIPS Article 31.[45]
The outbreak of some other deadly diseases, such as
the anthrax outbreak in the US and Canada after the 9/11 attacks, the
foot-and-mouth disease epidemic in the United Kingdom and other parts of
Europe, and the threat of a global bird flu pandemic on the eve of the 2005 WTO
ministerial meeting in Hong Kong attracted widespread public attention to WTO
rules on intellectual property rights in pharmaceuticals. These incidents
directly influenced WTO negotiations on intellectual property and played a
crucial role in shaping the public health provisions of TRIPS. After lengthy
and complex negotiation phases, the Doha Ministerial Declaration finally
emphasized the need to address the implementation and interpretation of TRIPS
flexibility provisions that address the challenges of developing countries.[46]
Due to this debate, Doha Declaration on TRIPS and Public Health (DDTPH) was
adopted in November 2001.[47]
Ultimately, a temporary waiver of TRIPS Article 31(f) was granted in August
2003. This temporary waiver became a permanent provision of TRIPS. In 2017, the
treaty was amended, and Article 31bis was incorporated permanently
as an exception to Article 31(f).[48]
The August 2003 waiver is now an essential part of TRIPS flexibilities within
TRIPS Article 31bis.[49]
As mentioned, a proposal aimed at facilitating
‘rapid access to affordable medical products’ was put forward on 2 October 2020
by South Africa and India.[50]
On 21 May 2021, following extensive discussion, and to address the comments by
other WTO members, such as that the initial proposal was too broad, a revised
proposal was submitted. This revised version concerns ‘health products and
technologies including diagnostics, therapeutics, vaccines, medical devices,
personal protective equipment, their materials or components, and their methods
and means of manufacture for the prevention, treatment or containment of
COVID-19.’[51]
It is proposed that the waiver would be in force for at least three years from
the date of the decision.[52]
On May 5, 2021, the United States expressed support
for the concept of a waiver of intellectual property rights limited to COVID-19
vaccines and pledged to "actively participate in text negotiations to make
that happen.”[53]
Support for the TRIPS waiver concept and/or on-going WTO discussions on it have
expanded to include some higher-income countries and economic groupings (e.g.
the BRICS nations of Brazil, Russia, and India, China and South Africa and the
19th-member Asia-Pacific Economic cooperation). Some other WTO members
continued to oppose or remain sceptical of the waiver proposals; these members
included the European Union (EU), Switzerland and the United Kingdom (UK). For
example, the EU presented an alternative proposal for fair access to vaccines
and treatments for COVID-19, with elements to reduce export restrictions and
maintain open supply chains, expand production and facilitate the use of CLs
under TRIPS, as appropriate.[54]
On March 15, 2022, the United States, the EU, India,
and South Africa—which the WTO termed the “Quad” came to a “compromise outcome”
agreement on the proposed waiver for COVID-19 vaccines[55] and the
proposal arose out of an informal process facilitated by the WTO
Director-General (DG) to come to an agreement.[56]
On May 3, the DG forwarded the text of the Quad’s
document to the full membership of WTO.[57] The
official resulting document was similar to the earlier reported version, the
primary difference being some additional text in parentheses (i.e., indicating
that such text was not agreed upon and is still being debated). At the WTO
General Council meeting on 10 May, WTO members agreed that the resulting
document opened up the prospect of textual negotiations on the intellectual
property rights response to COVID-19.[58] WTO
members reached a ministerial decision through consensus on a WTO TRIPS waiver
for COVID-19 vaccines on 17 June as part of a broader "Geneva
Package" of multilaterally negotiated outcomes at 12th
Ministerial Conference which was held from 12-17 June.[59]
TRIPS
WAIVER DECISION FOR COVID-19 VACCINES
The WTO Ministerial Decision on the TRIPS Agreement,
adopted on 17 June 2022, provides a five-year exemption from certain Compulsory
Licenses requirements for COVID-19 vaccines.[60] The
decision authorizes the authorized member to use the subject matter of the
patent, including the ingredients and processes necessary to manufacture a
COVID-19 vaccine, without the rights holder's consent through any instrument
available in the laws of that member that allows such permission (e.g.,
executive orders, emergency orders, and judicial or administrative ordinance).
Member does not need to have CL mode installed. In view of the
"exceptional circumstances of the COVID-19 pandemic", the decision
uses the powers set out in the WTO Marrakesh Agreement for the WTO Ministerial
Conference to waive the obligation imposed on a member "[in] exceptional
circumstances.”[61]
The
IP waiver has the potential to overcome some of the limitations of the
compulsory licensing system.[62]
These include the product-by-product requirement of compulsory licensing that
restricts the effective and speedy application of this mechanism, as well as
the need to spend time on identifying the patents that cover the products in
question prior to issuing a compulsory licence. With the adoption of the IP
waiver, these obstacles would be removed.[63]
Moreover,
the waiver would also remove the need to comply with the cumbersome procedure
of Article 31bis TRIPS in the case of exporting COVID-19 vaccines or medicines
to other countries with no or limited manufacturing capacity. With the adoption
of Waiver at WTO level, WTO members would not be able to sue a WTO member for
TRIPS non-compliance in the case where it waives IP rights at national level.
The effect of the IP waiver at national level, in turn, is that IP rights would
not be enforceable against third parties once the IP waiver is implemented into
domestic IP laws. Specifically, the national adoption of the IP waiver would
presuppose suspending the enforceability of IP rights, including obligations
under free trade agreements, and declaring that the manufacture of the
IP-protected products and other activities that fall within the exclusive
rights of the IP owner by third parties without their permission would not be
considered an infringement.[64]
This naturally empowers their owners to fully control these technologies,
preventing others from manufacturing COVID-19 related therapeutics without
their permission.[65]
CONCLUSION
The waiver of Outings of COVID?19
immunization is areas of strength for a compelling responsibility requested by
non-industrial nations. This paper attempted to investigate the effect of
waiver on agricultural nations and drug businesses, and how does the fantasy of
admittance to antibody by all be accomplished. The Excursions when it’s
previously appeared the non-industrial nations were a long ways behind their
doled out objective to conform to the standard. This is because of absence of
financial and different assets; the extraordinary pandemic has additionally
disabled it. There is a weighty lack of immunization not in emerging nations
but rather different countries too. The connection among Excursions and general
wellbeing is certainly not another one as Helps pandemic is clear of that. Be
that as it may, how Outings is to be administered in the singular country
actually relies upon its homegrown regulation. The 2020-2022 campaign for this
TRIPS waiver has proven to be the most significant challenge to the
international IP system in a generation, garnering support from more than 100
countries (the majority of which are developing countries) Members of the WTO).
The waiver campaign has depoliticized the IP landscape, changing the debate
over the legitimacy of IP law and transforming how public health concerns are
articulated in relation to IP. The waiver campaign has already achieved
significant results in the political and economic realms. It has increased
transparency about vaccine manufacturing and pricing as a result of the
pressure it has created.
The threat of the waiver has served as a
motivator for industry cooperation in voluntary technology transfers, knowledge
sharing, and participation in global initiatives such as the Medicines Patent
Reform Act. The public regulation held as a manual for steer the arrangements
of Outings toward any path where one country needs. There is an absence of
assembling limit in these non-industrial nations the adaptabilities gave in
Outings guideline are sufficiently not to build the assembling limit. The issue
isn't just of assembling yet in addition of the costs fixed by the separate
drug organizations. The admittance to immunization is a social right that ought
to be practiced by countries together. The Outings waiver assists in better
collaboration and coordination between the countries and which with advancing
aides in innovative work. The UN significant level board on admittance to
medication carefully guide state run administrations to abstain from any
movement that incorporates systems or strategies that sabotages the right of
WTO individuals to utilize Excursions. A
considerable lot of the nation’s make revisions in their homegrown regulations
to utilize necessary permitting. In the event that it is now in process the
Outings waiver somewhat will assist in access with medicating more
straightforward and faster. The created nations ought to approach and support
the choice of Excursions waiver in meeting WTO chamber meeting.
[1] Bruce Lehman, the Pharmaceutical
Industry and the Patent System (International Intellectual Property Institute,
2003), 2–14.
[2] Basma Ibrahim, Implications
of WTO?TRIPS Agreement from a National Innovation Systems Perspective (The
School of Public Policy and Administration, 2003).
[3] Thomas Cottier, The Doha
Waiver and its Effects on the Nature of the TRIPS System and on Competition
Law: The Impact of Human Rights, Swiss National Centre of competence in
Research. Working Paper no. 2006.
[4] Talat Chaudhay and Arshi
Chaudhary Faculty of Law, Jamia Millia Islamia University, New Delhi India
& Department of Pharmacology, Jamia Hamdard
University, New Delhi India, J World Intellect Prop. 2021 Nov; 24(5-6):
447–454.
[5] Prabhas Ranjan, the Case for
Waiving Intellectual Property Protection for Covid?19 Vaccines (Observer
Research Foundation, 2021).
[6] Ronald Lobante and Mira
Johri, COVID?19 Drug and Vaccine Patents Are Putting Profit Before
People (2020).
[7] Jessica L Greenbaum, 'Trips and
Public Health: Solutions for Ensuring Global Access to Essential AIDS
Medication in the Wake of Paragraph 6 Wake of paragraph 6 Waiver' (2008) 25
JCHLP 142.
[8] Donald Harris, 'TRIPS After Fifteen
Years: Success or Failure, as Measured by Compulsory Licensing' (2011) 18 JIPL.
369.
[9] Haochen Sun, 'The Road to Doha
& Beyond: Some Reflection on TRIPS Agreement and access to Public Health'
(2004) 15 EJIL 123.
[10] Benjamin Coriat, Fabienne Orsi and
Cristina d'Almeida, 'TRIPS and the International Public Health Controversies:
Issues and Challenges' (2006) 15 ICC 1033.
[11]
Article 30 of the TRIPS agreement. WTO.
[12]
Article 31 of the TRIPS agreement WTO.
[13] Weinian Hu, Compulsory
Licensing and Access to Future COVID 19 Vaccines, CEPS Research Report no. 2020
(2020).
[14] Benjamin Coriat, Fabienne Orsi and
Cristina d'Almeida, 'TRIPS and the International Public Health Controversies:
Issues and Challenges' (2006) 15 ICC 1033.
[15] Frederick M Abbott, 'The Doha
Declaration on TRIPS and Public Health' (2002) 5 JIEL 469.
[16] Ibid.
[17] Kenneth C Shadlen, Patents
and Pills, Power and Procedure: The North?South Politics of Public Health in
the WTO, Studies in Comparative International Development (Vol. 39, 2002).
[18] Emmanuel
Kolawole Oke, THE WAIVER OF THE TRIPS
AGREEMENT FOR COVID-19 AT THE WTO: A RHETORICAL ANALYSIS, Lecturer in
International Intellectual Property Law, Edinburgh Law School, University of
Edinburgh.
[19] Bradly Condon and Tapen Sinha,
'Global Diseases, Global Patents and Differential Treatment in WTO Law:
Criteria for Suspending Patent Obligations in Developing Countries' (2006) 26
NJILB 1.
[20] Alan O Sykes, TRIPs,
Pharmaceuticals, Developing Countries, and the Doha "Solution", John
M. Olin Program in Law and Economics Working Paper No. 140 (2002).
[21] Kenneth C Shadlen, 'Patents and
Pills, Power and Procedure: The North?South Politi of Public Health in the WTO'
(2004) 39 SCID 76.
[22] Salla Sariola, 'Intellectual
Property Rights Need to be Subverted to Ensure Global Vaccine Access' BMJ
GHJ .
[23] Sushil Vachani and N. Craig
Smith, Lessons from Pricing of AIDS Drugs in Developing Countries. Working
Paper No. 03?703b. London Business School (2004).
[24] Human Rights Watch, Seven
Reasons the EU is Wrong to Oppose the TRIPS Waiver (2021).
[25] Richard Wilder and Eric M Solovy, The
Development of Medicines for Developing Country Diseases: The Role of
Intellectual Property. WIPO (2004).
[26] Medicines Sans Fronteires (MSF), Access Campaign.
WTO COVID?19 TRIPS Waiver Proposal (2021).
[27] Ashok Dhingra, Waiver Under
TRIPS Agreement Needed More Urgently Now (2021).
[28] Ibid.
[29] Guy Martin, TRIPS Waiver: Is
the US Backing a Cause For Concern For Pharma? The Pharmaletter (2021).
[30] Art Gonzales, The TRIPS
waiver on Covid?19 Pharmaceuticals and the Big Pharma (2021).
[31] Catherine Saez, Main
Recommendations of UN High?Level Panel on Access to Medicines Presented at
WTO (2017).
[32] Alan O Sykes, TRIPs,
Pharmaceuticals, Developing Countries, and the Doha "Solution", John
M. Olin Program in Law and Economics Working Paper No. 140 (2002).
[33] Correa (n 13) 3; Yousuf Vawda,
‘The TRIPS COVID-19 Waiver, Challenges for Africa and Decolonizing Intellectual
Property’ (South Centre, Policy Brief No 99, 2021).
[34] Thambisetty, McMahon, McDonagh,
Kang and Dutfield (n 13) 399.
[35] Frederick Abbott, The TRIPS Agreement
Article 73 Security Exceptions and the COVID-19 Pandemic (South Centre,
Research Paper No 116, 2020) 21; Carlos Correa, ‘COVID-19 Pandemic: Access to
Prevention and Treatment Is a Matter of National and International Security’
(South Centre, 4 April 2020).
[36]. Peter K Yu, ‘Modalities,
Challenges, and Possibilities: An Introduction to the Pharmaceutical Innovation
Symposium’ (2021) 7 Texas A&M Journal of Property Law 1, 11.
[37] D Ravi Kanth, ‘WTO: US Storms Out
from Discussions on WTO Response to Pandemic’ (TWN Info Service on WTO and
Trade Issues, 8 June (2022).
[38]World Intellectual Property
Organization, COVID-19-Related Vaccines and Therapeutics: Preliminary Insights
on Related Patenting Activity During the Pandemic (Geneva: World Intellectual
Property Organization 2022.
[39] Peter K Yu, ‘Deferring
Intellectual Property Rights in Pandemic Times’ (2023) 74 Hastings Law Journal.
[40] Jean-Frédéric Morin and E Richard
Gold, ‘Consensus-seeking, Distrust and Rhetorical Entrapment: The WTO Decision
on Access to Medicines,’ (2010) 16(4) European Journal of International
Relations 563, 566.
[41] Communication from India and South Africa, ‘Waiver from
Certain Provisions of the Trips Agreement for the Prevention, Containment and
Treatment of Covid-19’ (2 October 2020) IP/C/W/669 accessed 21 May 2021.
[42] Minutes of the Meeting: Held in the Centre William
Rappard from 2 to 5 April 2001, WTO Doc IP/C/M/30 (1 June 2001) (paras 229–52)
(Council for Trade-Related Aspects of Intellectual Property Rights).
[43] D Gervais, The TRIPS Agreement: Drafting
History and Analysis (London, Sweet and Maxwell 2003) pp
32–43.
[44] Ibid.
[45] Ibid.
[46] Ministerial Declaration, WTO Doc WT/MIN(01)/DEC/1 (20
November 2001) (Para 17) (Ministerial Conference, Fourth Session, Doha, 9–14
December 2001).
[47] Doha WTO Ministerial 2001: TRIPS
WT/MIN(01)/DEC/2, “Declaration on the TRIPS Agreement and Public Health
(Adopted 14 November 2001)” (WTO, 20 November
2001).
[48] WTO: 2017 News Item, “WTO IP Rules Amended to Ease Poor
Countries’ Access to Affordable Medicines” (WTO, 23 January
2017) <https://www.wto.org/english/news_e/news17_e/trip_23jan17_e.htm>
(last accessed 16 July 2021).
[49] W New, “It’s Official: TRIPS Health Amendment In Effect,
First Ever to a WTO Agreement” (Intellectual Property Watch,
23 January 2017) <https://www.ip-watch.org/2017/01/23/official-trips-health-amendment-effect-first-ever-wto-agreement/>
(last accessed 12 July 2021).
[50] Communication from India and South
Africa (n 8).
[51] ibid, Para 1 of the draft
decision.
[52] ibid, Para 3 of the draft
decision.
[53] USTR, “Statement from Ambassador Katherine
Tai on the COVID-19 TRIPS Waiver,” press release, May 5, 2021.
[54] European Commission, “EU Proposes
a Strong Multilateral Trade Response to the COVID-19 Pandemic,” press release,
June 4, 2021.
[55] WTO, DG, “Director-General
Okonjo-Iweala Hails Breakthrough on TRIPS COVID-19 Solution,” press release,
March 16, 2022.
[56] WTO, “Members Updated on
High-Level Talks Aimed at Finding Convergence on IP COVID-19 Response,” press
release, March 10, 2022.
[58] WTO, General Council, “Members
Welcome Quad Document as Basis for Text-Based Negotiations on Pandemic IP
Response,” May 10, 2022.
[59] WTO, “Ministerial Decision on the
TRIPS Agreement” (adopted on June 17, 2022), WT/MIN(22)/30, WT/L/1141, June 22,
2022.
[62] Compulsory licensing v the IP
waiver: what is the best way to end the COVID-19 pandemic? the South Centre
policy brief by Olga Gurgula
[63] Compulsory licensing v the IP
waiver: what is the best way to end the COVID-19 pandemic? the South Centre
policy brief by Olga Gurgula
[64] See, e.g., Carlos M. Correa,
Nirmalya Syam and Daniel Uribe, ‘Implementation of a TRIPS Waiver for Health
Technologies and Products for COVID-19: Preventing Claims Under Free Trade and
Investment Agreements’ (September 2021) the South Centre Research Paper 135.
Available _Implementation-of-a-TRIPS-Waiver-for-Health-Technologies-and-Products-forCOVID-19_EN.pdf.
Article Information
TRIPS WAIVER : THE HUMANITARIAN SAVIOUR DURING COVID-19 PANDEMIC
Authors: RUCHITA SRIVASTAVA, KUMARI PRAGATI
- Journal IJLRA
- ISSN 2582-6433
- Published 2023/04/24
- Volume 2
- Issue 7
About Journal
International Journal for Legal Research and Analysis
- Abbreviation IJLRA
- ISSN 2582-6433
- Access Open Access
- License CC 4.0
All research articles published in International Journal for Legal Research and Analysis are open access and available to read, download and share, subject to proper citation of the original work.
Disclaimer: The opinions expressed in this publication are those of the authors and do not necessarily reflect the views of International Journal for Legal Research and Analysis.